| Property | Value |
|---|
|
?:abstract
|
-
OBJECTIVE: Significant morbidity and mortality from SARS-CoV-2 has been experienced in America, Europe and Asia; whereas, the number of infections and deaths in sub-Sahara Africa (SSA) has remained comparatively low. One hypothesis is that population in SSA has been exposed to other coronaviruses prior to the COVID-19 pandemic and resulted in some degree of cross-protection against SARS-CoV-2 infection and pathogenesis. Our goal was to evaluate this hypothesis by comparing SARS-CoV-2 cross-reactive antibodies in pre-pandemic plasma samples collected from SSA and USA. METHOD: Pre-COVID-19 pandemic plasma samples from SSA and USA were collected and tested by immunofluorescence assay against the spike and nucleocapid proteins of all known human coronaviruses (HCoV). RESULTS: Significantly higher prevalence of SARS-CoV-2 serological cross-reactivity was detected in samples from SSA compared to USA. Majority of these cross-reactive samples cross-recognized SARS-CoV-2 nucleocapsid protein together with recognition of spike proteins from other HCoVs. Since nucleocapsid proteins from HCoV-NL63 and HCoV-229E were detected by majority of samples, it implicates prior exposure to these two HCoVs as the likely source for cross-reactive antibodies against SARS-CoV-2. CONCLUSION: Low SARS-CoV-2 infection and disease in SSA appears to correlate with pre-pandemic serological cross-recognition of HCoVs, which are substantially more prevalent in SSA than USA.
|
|
is
?:annotates
of
|
|
|
?:creator
|
|
|
?:doi
|
-
10.1016/j.ijid.2020.10.104
|
|
?:doi
|
|
|
?:journal
|
|
|
?:license
|
|
|
?:pdf_json_files
|
-
document_parses/pdf_json/e6b7d0c616677e75e8f2f46eb2cf421250dfdfdf.json
|
|
?:pmc_json_files
|
-
document_parses/pmc_json/PMC7648883.xml.json
|
|
?:pmcid
|
|
|
?:pmid
|
|
|
?:pmid
|
|
|
?:publication_isRelatedTo_Disease
|
|
|
is
?:relation_isRelatedTo_publication
of
|
|
|
?:sha_id
|
|
|
?:source
|
|
|
?:title
|
-
High prevalence of pre-existing serological cross-reactivity against SARS-CoV-2 in sub-Sahara Africa
|
|
?:type
|
|
|
?:year
|
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}